This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Status:
Completed
Trial end date:
2020-07-02
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in
patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding
requiring urgent intervention, and in patients treated with dabigatran etexilate who require
emergency surgery or other invasive procedure.
The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the
clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of
idarucizumab.